Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus PREMPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus PREMPRO.
DIETHYLSTILBESTROL vs PREMPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
PREMPRO is a combination of conjugated estrogens and medroxyprogesterone acetate. Estrogens bind to estrogen receptors, activating gene transcription and exerting effects on various tissues. Medroxyprogesterone acetate is a progestin that suppresses endometrial proliferation, reducing the risk of endometrial hyperplasia associated with unopposed estrogen therapy.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
One tablet orally once daily; each tablet contains conjugated estrogens 0.625 mg and medroxyprogesterone acetate 2.5 mg or 5 mg.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
The terminal elimination half-life of conjugated estrogens (primarily estrone and equilin) ranges from 10-24 hours (mean ~15 hours) after oral administration. This supports once-daily dosing with steady-state achieved within 5-7 days.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Conjugated estrogens are primarily excreted in urine (renal elimination accounts for ~50-80% of total clearance) as glucuronide and sulfate conjugates. A smaller fraction undergoes biliary excretion (~10-20%) and is eliminated in feces via enterohepatic circulation.
Category C
Category C
Estrogen
Estrogen/Progestin Combination
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."